Loading…
No business profile yet.
Size Handa Pharmaceuticals (6620.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $525M, the 429th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$104.50 on 6 Nov 2026.
Performance Over six months the shares gained 42.8%, against -18.9% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 67.5% over the last twelve months (peer median +9.4%); the operating margin is 37.5% (peer median 6.8%).
Valuation It trades at 21.6× forward earnings against a peer median of 13.0× (most expensive of 5).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +127%, so the hurdle is -114 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 20.9 points above its cost of capital (6.3% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.21B | NT$1.73B | NT$831M | NT$1.11B | NT$198M |
| Revenue growth | — | +108% | -25% | +460% | — |
| Gross profit | NT$972M | NT$1.45B | NT$819M | NT$1.09B | NT$164M |
| EBITDA | NT$618M | NT$1.10B | NT$428M | NT$706M | -NT$72.9M |
| Net income | NT$490M | NT$750M | NT$473M | NT$727M | -NT$40.0M |
| Free cash flow | n/a | NT$227M | NT$490M | NT$667M | -NT$212M |
| Capital expenditure | n/a | NT$17.1M | NT$7.77M | NT$944,000 | NT$758,000 |
| Total debt | NT$41.0M | NT$47.6M | NT$40.1M | NT$13.2M | NT$29.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6620.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -28.4% | -8.0% | 3rd lowest of 21 |
| 6-month return | +42.8% | -18.9% | 5th highest of 21 |
| Distance from 52-week high | -32.6% | -37.2% | 10th highest of 21 |
| Revenue growth (TTM) | +67.5% | +9.4% | highest of 20 |
| Operating margin | 37.5% | 6.8% | 3rd highest of 18 |
| Forward P/E | 21.6× | 13.0× | most expensive of 5 |
| Growth the price implies (Req g, 7 yrs) | 12.9% | 1.4% | 3rd most demanding of 9 |
| Growth delivered (Del g) | +126.7% | +8.4% | highest of 9 |
| Hurdle (Req g minus delivered) | -113.9 pp | -5.2 pp | least demanding of 9 |
| ROIC minus cost of capital | +20.9 pp | -3.1 pp | 4th highest of 19 |
| EV / EBITDA | 22.1× | 18.3× | 2nd most expensive of 4 |
| Net debt / EBITDA | -6.0× | 0.3× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 21.6× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | n/a | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 14.9× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 19.5× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | n/a | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 11.1× | -8.9% | +12.6% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | n/a | 17.7% | +4.4% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | n/a | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | n/a | -5.2% | +9.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 9.3× | -12.5% | +11.1% |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | n/a | -3.9% | +7.6% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | n/a | 47.1% | -12.3% |